Show simple item record

dc.contributor.authorGuo, Y
dc.contributor.authorKarimi, F
dc.contributor.authorFu, Q
dc.contributor.authorG Qiao, G
dc.contributor.authorZhang, H
dc.date.accessioned2021-01-14T04:58:45Z
dc.date.available2021-01-14T04:58:45Z
dc.date.issued2020-02-03
dc.identifier.citationGuo, Y., Karimi, F., Fu, Q., G Qiao, G. & Zhang, H. (2020). Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution.. Expert Opin Drug Deliv, 17 (3), pp.407-421. https://doi.org/10.1080/17425247.2020.1719995.
dc.identifier.issn1742-5247
dc.identifier.urihttp://hdl.handle.net/11343/258691
dc.description.abstractBackground: Natamycin is the only topical ophthalmic antifungal drug approved by the Food and Drug Administration (FDA) of the United States, but has unsatisfactory factors such as high dosing frequency.Methods: We report the synthesis and preparation of self-assembled poly(ethylene glycol)-block-poly(glycidyl methacrylate) (PEG-b-PGMA) micelles. These nanoparticles exhibit sustained delivery of a hydrophobic natamycin by topical administration on eye due to the hydrolysable properties of PGMA segments of micelle. Hydrolysis of glycidyl groups within a physiologically relevant environment provides an additional driving force for drug release by generation of hydrophilic hydroxyl groups to 'push' the encapsulated hydrophobic drug away from the resultant hydrophilic domains and into surrounding environment.Results: In vitro and in vivo results revealed that the self-assembled micelles and the encapsulated natamycin were not cytotoxic and the released drug have strong antifungal ability to Candida albicans. Importantly, sustained natamycin release from micelles leads to the reduced administration frequency of natamycin from 8 times per day to 3 times per day in rabbits suffering from fungal keratitis (FK).Conclusion: This study demonstrates a facile method that can greatly reduce dosing frequency of natamycin administration and thus improve long-term patient compliance.
dc.languageeng
dc.publisherTaylor & Francis Ltd
dc.titleReduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution.
dc.typeJournal Article
dc.identifier.doi10.1080/17425247.2020.1719995
melbourne.affiliation.departmentChemical and Biomolecular Engineering
melbourne.source.titleExpert Opinion on Drug Delivery
melbourne.source.volume17
melbourne.source.issue3
melbourne.source.pages407-421
melbourne.identifier.arcLP150100315
melbourne.elementsid1435232
melbourne.internal.embargodate2021-02-03
melbourne.contributor.authorKarimi, Fatemeh
melbourne.contributor.authorGUO, YIYUAN
melbourne.contributor.authorFu, Qiang
melbourne.contributor.authorQiao, Greg
dc.identifier.eissn1744-7593
melbourne.identifier.fundernameidAustralian Research Council, LP150100315
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record